Form 8-K Tracon Pharmaceuticals, For: Sep 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St set for higher open after retail earnings; Moderna soars
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
TRACON Pharmaceutical (TCON) Offers Additional Detail on Janssen Licensing Agreement
September 28, 2016 4:41 PM EDTTRACON Pharmaceutical (NASDAQ: TCON) disclosed the following in a U.S. SEC filing on Wednesday:
Item 1.01 - Entry into a Material Definitive Agreement.
On September 27, 2016, TRACON Pharmaceuticals, Inc. (the Company) entered into separate transactions with Janssen Pharmaceutica N.V. (Janssen) and its affiliate, Johnson & Johnson Innovation-JJDC, Inc. (JJDC) consisting of a license and option agreement with Janssen (the License and Option Agreement) and a stock purchase agreement and investor agreement, each with JJDC (the Stock Purchase Agreement and the Investor Agreement, respectively).
License and Option Agreement
Under the License and Option Agreement, Janssen granted the... More
